Showing 3121-3130 of 7638 results for "".
- La Fondation La Roche-Posay (North American) Awards 2020 Grant Winnershttps://practicaldermatology.com/news/la-fondation-la-roche-posay-north-american-awards-2020-grant-winners/2460363/And the five La Fondation La Roche-Posay (North America) 2020 research grant winners in the field of dermatology are… Dawn Zhang Eichenfield, MD, PhD, Chief Dermatology Resident at the University of California, San Diego. She received the first place prize of $10,000 for her project, Identificati…
- Prescriber’s Choice Launches “PC Direct” and “PC Delivers”https://practicaldermatology.com/news/prescribers-choice-launches-pc-direct-and-pc-delivers/2460362/Two new options from Prescriber’s Choice enable physicians to prescribe and ship medicines directly to patients for the treatment of dozens of dermatologic conditions. The ability to ship Prescriber’s Choice medicines to patients is an alternative to existing in-office dispensing to support the cur…
- R2 Technologies Receives $10M Second Tranche Investment for CryoAesthetic Technologyhttps://practicaldermatology.com/news/r2-technologies-receives-10m-second-tranche-investment-for-cryoaesthetic-technology/2460361/R2 Technologies Inc. scored $10 million in funding from Huadong Medicine Company Limited to help to commercialize their CryoAesthetic technology, which reduces the appearance of sun damage and uneven skin tone. The CryoAesthetic procedure is cleared for removal of benign lesions. It was slated to …
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate to severe scalp psoriasis…
- COVID-19 By the Numbers: April 21 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-21-edition/2460357/More than 300,000 Americans could die if all social distancing measures are abandoned, according to documents obtained by the Center for Public Integrity and reported in conjunction with NPR. Some experts argue those figures are conservative. With distancing in place, the Institute for Health Met…
- Coping with COVID-19: Tips and Tools for Enhancing Virtual Skin Cancer Examshttps://practicaldermatology.com/news/coping-with-covid-19-tips-and-tools-for-enhancing-virtual-skin-cancer-exams-1/2460356/Dermatologists across the country have shut their doors due to the coronavirus pandemic, and little certainty remains about when they will reopen for business as usual. Many are still seeing patients with aggressive squamous cell carcinoma or melanoma, but these patients need to be effectively tria…
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC) in patients aged…
- Industry Responds to COVID-19: UCB, Galderma, Timeless Skin Carehttps://practicaldermatology.com/news/industry-responds-to-covid-19-ucb-galderma-timeless-skin-care/2460354/UCB. UCB is working with the Seattle Structural Genomics Center for Infectious Disease to identify crystal structures of SARS-CoV-2 proteins. In addition to providing funding support to organizations in need during this challenging time, UCB’s research facility in Bedford, Massachusetts, donated sa…
- DermWire Exclusive: Inside the COVID-19 Outbreak in Italy with Dr. Sebastiano Recalcatihttps://practicaldermatology.com/news/dermwire-covid-19-exclusive-inside-the-outbreak-in-italy-with-sebastiano-recalcati/2460352/Dr. Sebastiano Recalcati, a dermatologist in Lombardy, Italy, was one of many doctors called to the frontlines in that country when COVID-19 ravaged the region. He published his observations in the Journal of the European Academy of Dermatology Venereology. Dr. Recalcati spoke to DermWire and Pract…
- Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases/2460351/Kubota Vision Inc. signed an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop novel therapeuti…